Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial
接触激活抑制剂和因子XI抗体AB023在首次人体I期试验中显示出安全、剂量依赖性的抗凝血作用。
期刊:Arteriosclerosis Thrombosis and Vascular Biology
影响因子:7.4
doi:10.1161/ATVBAHA.118.312328
Lorentz, Christina U; Verbout, Norah G; Wallisch, Michael; Hagen, Matthew W; Shatzel, Joseph J; Olson, Sven R; Puy, Cristina; Hinds, Monica T; McCarty, Owen J T; Gailani, David; Gruber, András; Tucker, Erik I